KID3 and KID3 antibodies that bind thereto

1. A method of inhibiting the growth of a cancer cell that expresses KID3 in an individual, wherein said method comprises administering to said individual an effective amount of a composition comprising an anti-KID3 antibody, wherein said anti-KID3 antibody is an antibody expressed by the hybridoma having ATCC Deposit No. PTA-4860, or an antibody that specifically binds to the same epitope on KID3 as said antibody expressed by the hybridoma having ATCC Deposit No. PTA-4860 specifically binds.

2. The method of claim 1 , wherein said anti-KID3 antibody is a humanized antibody.

3. The method of claim 1 , wherein said anti-KID3 antibody comprises the three CDRs from the heavy chain and the three CDRs from the light chain of the antibody expressed by the hybridoma having ATCC Deposit No. PTA-4860.

4. The method of claim 3 , wherein said anti-KID3 antibody is a humanized antibody.

5. The method of claim 1 , wherein said anti-KID3 antibody is associated with a chemotherapeutic agent.

6. The method of claim 1 , wherein said chemotherapeutic agent is a radioactive molecule, a toxin or a cytotoxin.

7. The method of claim 5 , wherein the chemotherapeutic agent is delivered into the cancer cell.

8. The method of claim 1 , wherein said cancer cell is selected from the group consisting of a cancer cell from: an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, a bladder cancer, a bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumor, a cervical cancer, a chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing's tumor, an extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder and bile duct cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, an islet cell tumors, a Kaposi's Sarcoma, a kidney cancer, a leukemia, a lipoma/benign lipomatous tumor, a liposarcoma/malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a neuroendocrine tumor, an ovarian cancer, a pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterious uveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomysarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.

9. The method of claim 8 , wherein said cancer cell is a bladder cancer cell, said bladder cancer cell being a squamous cell carcinoma or a transitional cell carcinoma.

10. The method of claim 8 , wherein said cancer cell is a bone cancer cell, said bone cancer cell being an adamantinoma, a aneurismal bone cyst cell, an osteochondroma cell or an osteosarcoma cell.

11. The method of claim 8 , wherein said cancer cell is a kidney cancer cell, said kidney cancer cell being a nephroblastoma cell or a papillary renal cell carcinoma cell.

12. The method of claim 8 , wherein said cancer cell is a liver cancer cell, said liver cancer cell being a hepatoblastoma cell or a hepatocellular carcinoma cell.

13. The method of claim 8 , wherein said cancer cell is a uterine cancer cell, said uterine cancer cell being a cell of a carcinoma of the cervix, an endometrial carcinoma cell or a leiomyoma cell.

14. The method of claim 8 , wherein said cancer cell is a colon cancer cell, said colon cancer cell being a colon adenocarcinoma cell or a colorectal adenocarcinoma cell.